{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:14:03Z","timestamp":1781043243737,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00198-024-07260-9","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:01:25Z","timestamp":1727654485000},"page":"2175-2182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"7260_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376","journal-title":"Lancet"},{"key":"7260_CR2","first-page":"130","volume":"S1","author":"Kidney Disease: Improving Global Outcomes CKDMBD WG","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes CKDMBD WG (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl S1:130","journal-title":"Kidney Int Suppl"},{"key":"7260_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","volume":"14","author":"SM Moe","year":"2007","unstructured":"Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 14:3\u201312","journal-title":"Adv Chronic Kidney Dis"},{"key":"7260_CR4","doi-asserted-by":"publisher","first-page":"101650","DOI":"10.1016\/j.bonr.2022.101650","volume":"18","author":"S Qiu","year":"2022","unstructured":"Qiu S, Divine G, Rao SD (2022) Effect of vitamin D metabolites on bone histomorphometry in healthy black and white women: an attempt to unravel the so-called vitamin D paradox in blacks. Bone Rep 18:101650","journal-title":"Bone Rep"},{"key":"7260_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/nu15010167","volume":"15","author":"E Bellorin-Font","year":"2023","unstructured":"Bellorin-Font E, Rojas E, Martin KJ (2023) Bone disease in chronic kidney disease and kidney transplant. Nutrients 15:167. https:\/\/doi.org\/10.3390\/nu15010167","journal-title":"Nutrients"},{"key":"7260_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL et al (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396\u2013399","journal-title":"Kidney Int"},{"key":"7260_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, Pouget JG, Lok CE, Hodsman AB, Adachi JD, Garg AX (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810\u2013818. https:\/\/doi.org\/10.1038\/ki.2013.547","journal-title":"Kidney Int"},{"key":"7260_CR8","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","volume":"56","author":"K Nitta","year":"2017","unstructured":"Nitta K, Yajima A, Tsuchiya K (2017) Management of osteoporosis in chronic kidney disease. Intern Med 56:3271\u20133276","journal-title":"Intern Med"},{"key":"7260_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"7260_CR10","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106. https:\/\/doi.org\/10.1210\/jc.2011-3479","journal-title":"J Clin Endocrinol Metab"},{"key":"7260_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE et al (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res 22:503\u2013508","journal-title":"J Bone Miner Res"},{"key":"7260_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"7260_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59\u201368","journal-title":"Osteoporos Int"},{"key":"7260_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang Y-C, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835","journal-title":"J Bone Miner Res"},{"key":"7260_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37:1437\u20131445","journal-title":"J Bone Miner Res"},{"key":"7260_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). J Bone Miner Metab 38:412\u2013417","journal-title":"J Bone Miner Metab"},{"key":"7260_CR17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S et al (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301\u20132311","journal-title":"Osteoporos Int"},{"key":"7260_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","volume":"34","author":"S Mori","year":"2023","unstructured":"Mori S, Hagino H, Sugimoto T et al (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189\u2013199","journal-title":"Osteoporos Int"},{"key":"7260_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"7260_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"7260_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0169-6009(08)80100-6","volume":"23","author":"L van Doorn","year":"1993","unstructured":"van Doorn L, Lips P, Netelenbos JC, Hackeng WH (1993) Bone histomorphometry and serum concentrations of intact parathyroid hormone (PTH(1\u201384)) in patients with primary hyperparathyroidism. Bone Miner 23:233\u2013242. https:\/\/doi.org\/10.1016\/s0169-6009(08)80100-6","journal-title":"Bone Miner"},{"key":"7260_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2265.2008.03187.x","volume":"69","author":"S Yamada","year":"2008","unstructured":"Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf) 69:189\u2013196","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07260-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:42:51Z","timestamp":1732095771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07260-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7260"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07260-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Y. Takeuchi has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharma Co., Ltd., and Teijin Pharma Ltd.S. Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Company, Limited, Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development.H. Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.S. Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd.T. Kuroda and S. Mori declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}